ASPEN

Evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations over the 52-week treatment period

Name of study: 
ASPEN: Evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations over the 52-week treatment period. 

Targeted disease: 
Non-Cystic Fibrosis Bronchiectasis

Purpose of study:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis  

Is this a pre- or post- market study?: 
Pre-Market Study

Is the study of a controlled or observational design? 
Controlled

What is the funding source?: 
Insmed Incorporated

Where is the study being conducted?
Multi-Center Trial

Lead Institution:
Multi-Center Trial

City and State: 
Nationwide

When the study is being conducted: 
Start Date:11/10/2020
End date: 3/31/2024

What website should a person use to register for the study?
https://www.patientwing.com/ASPEN-ALA 

Who should a person contact to register for the study?
Name: PatientWing
Phone: (213) 549-2979
Email: [email protected] 

Who is sponsoring this study?
Insmed Incorporated

What is the identifier for this study on ClinicalTrials.gov?
NCT04594369 

Page last updated: February 23, 2021

Freedom From Smoking Clinic
, | Sep 29, 2021
ONE Step Training Online
, | Oct 20, 2021